Merck’s (KEYTRUDA in combination with ALIMTA and Pt CT) Receives EU Approval for 1L mNonsq NSCLC with no EGFR or ALK Genomic Tumour

 Merck’s (KEYTRUDA in combination with ALIMTA and Pt CT) Receives EU Approval for 1L mNonsq NSCLC with no EGFR or ALK Genomic Tumour

Merck’s (KEYTRUDA in combination with ALIMTA and Pt CT) Receives EU Approval for 1L mNonsq NSCLC with no EGFR or ALK Genomic Tumour

Shots:

  • The approval is based on KEYNOTE-189 P-III study, assessing (KEYTRUDA + pemetrexed ALIMTA and Pt CT vs CT alone) administering KEYTRUDA 200 mg, cisplatin/carboplatin, and pemetrexed q3w IV for four cycles followed by KEYTRUDA 200 mg for up to 24 mos and pemetrexed q3w or (PBO + cisplatin/carboplatin and pemetrexed) q3w IV for four cycles followed by pemetrexed q3w
  • P-III KEYNOTE-189 study demonstrated: reducing risk of death by 51%; 48% reduction in the risk of progression/death; ORR (48% vs 19%); DOR (11.2 vs 7.8mos)
  • EU approval allows marketing of Keytruda (200mg q3w) + combination in Iceland, Lichtenstein, Norway and in 28 EU member states

Click here to read full press release/ article | Ref: Merck | Image: Caixin Global

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post